Erez Vigodman

ADAMA Agricultural Solutions Ltd. engages in the development, manufacture, and sale of crop and non-crop protection products. Its products and services include weed control, pest control, disease control, crop enhancers, and seed treatment. The company was founded in December 1997 and is headquartered in Tel Aviv, Israel.

Strauss Elite Holdings Ltd. provides food packaging services. It provides services to different parts of Israel. The company is located in Ramat Gan, Israel

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Aliment Capital LLC (Aliment Capital) is a venture capital subsidiary of Pontifax Management Co. Ltd. founded in 2014 by Philip Robert Erlanger and Ben Belldegrun. The firm is headquartered in California, United States.

Tropic Biosciences UK Ltd. develops varieties of tropical crops by utilizing cutting-edge genome editing technologies. The company is headquartered in Norwich, the United Kingdom.

Largix Tech Ltd. is an Israeli company that offers an additive production system (APS) which reduces manpower dependencies and increases productivity. The company is based in Tsur Yigal, Israel and was founded in 2015 by Ronen Orr and Amir Sheelo. The company's APS can be used in various industries such as storage tanks construction, urban architecture, aerospace, and automotive. Largix's cold 3D laser printing technology allows them to print in materials that other companies cannot, making them unique in the market. The APS can improve productivity by x15 and cut production costs in half. Ronen Orr has been the CEO since 2015. According to Geert Denutte, the founder of CGK, Largix's technology will be a game changer and estimates it will save them up to 50 percent in costs.

Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables.